video1.0<iframe src="https://www.loom.com/embed/1f434f727b88410091ed976147b79506" frameborder="0" width="1734" height="1300" webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>13001734Loomhttps://www.loom.com13001734https://cdn.loom.com/sessions/thumbnails/1f434f727b88410091ed976147b79506-df5e0994b8da0fc9.gif418.393333I walk through a Clinical Action Safety Review that turns a fragmented oncology chart into MayaR governed patient state. Maya is 62 with metastatic EGFR mutant non small cell lung cancer on osymertinib, with suspected progression, impaired renal function, anemia 9.4, borderline platelets 142, CKD, possible infection not excluded, and a prior carboplatin reaction. Because infection and renal and marrow gates are open, I conclude do not escalate yet, continue tolerated therapy while completing infection workup, repeat CBC, renal dosing review, and confirm progression. After gates close, escalation such as amivantamab plus lazertinib can be reconsidered. No viewer action was requested beyond following the plan.